



RESULTS
YOU CAN
TRUST.

Before and during biologic therapy

T-SPOT[®] TB

A MOMENT OF TRUTH



EASY

1 tube, 1 visit using routine phlebotomy and no pre-analytical steps.¹

By utilizing standard phlebotomy practices and ensuring that all up-front processing of the specimen after blood draw is done in a laboratory setting, controlled conditions are leveraged to mitigate impact of confounding variables associated with pre-analytical complexity.

ACCURATE

Extensively studied and **proven to perform in immunosuppressed patient populations** so you can minimize repeat tests.¹

The T-SPOT.TB test is the only interferon-gamma release assay (IGRA) with both sensitivity and specificity above 95% and an **invalid rate of less than 1%** in a study of over 645,000 tests.^{1,2}

ACCESSIBLE

Available through all Quest Diagnostics® Patient Service Centers and numerous regional laboratory partners.

The only IGRA without a warning or limitation in its package insert for screening immunocompromised individuals^{1,3}

Comparison of IGRA tests performance in patients with confirmed TB⁴

| Underlying condition | | |
|---------------------------|------------|----------------|
| End-stage renal disease: | 8 | (4.0%) |
| Liver cirrhosis: | 6 | (3.0%) |
| Diabetes mellitus: | 53 | (26.5%) |
| Solid cancer: | 34 | (17.0%) |
| Hematologic cancer: | 13 | (6.5%) |
| Steroid usage: | 35 | (17.5%) |
| Immunosuppressant: | 6 | (3.0%) |
| Transplant recipients: | 5 | (2.5%) |
| HIV infection: | 16 | (8.0%) |
| Autoimmune disorder: | 10 | (5.0%) |
| Immunocompromised: | 186 | (93.0%) |

Sensitivity of the ELISPOT test is higher than the ELISA in patients with active TB*

| | Patient group | ELISPOT | ELISA |
|---------------|-----------------------------------|--------------|--------------|
| Sensitivity | Culture confirmed TB | 88% (86/98) | 65% (64/98) |
| Sensitivity | Culture confirmed and probable TB | 83% (96/115) | 66% (71/108) |
| Indeterminate | All enrolled | N/A | 7% (14/200) |
| Invalid | All enrolled | 2% (4/200) | N/A |

*Including confirmed and probable TB

Visit TSPOT.COM for more information

REFERENCES:

- Oxford Immunotec. T-SPOT.TB Package Insert PI-TB-US-0001 V8. Abingdon, UK. September 2020.
- Rego K, Pereira K, MacDougall J, Cruikshank W. Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off point. *Tuberculosis*. 2018;108:178-185. doi:10.1016/j.tube.2017.12.005.
- Qiagen. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. 1095849 Rev. 06. November 2019.
- Lai CC, Tan CK, et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. *J Microbiol Immunol Infect*. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.

T-SPOT®.TB

Oxford Immunotec

T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd. Quest Diagnostics is a registered trademark of Quest Diagnostics. © 2021 Oxford Immunotec. All rights reserved. TB-US-LP-MPN406-0001 V1